21,714 Shares in Kenvue Inc. $KVUE Acquired by World Investment Advisors

World Investment Advisors acquired a new stake in Kenvue Inc. (NYSE:KVUE) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 21,714 shares of the company’s stock, valued at approximately $454,000.

Other institutional investors also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC increased its position in shares of Kenvue by 1.7% in the first quarter. Allspring Global Investments Holdings LLC now owns 87,136 shares of the company’s stock valued at $2,081,000 after buying an additional 1,477 shares in the last quarter. Mutual Advisors LLC boosted its position in shares of Kenvue by 5.7% in the 1st quarter. Mutual Advisors LLC now owns 15,994 shares of the company’s stock worth $368,000 after buying an additional 867 shares in the last quarter. OneDigital Investment Advisors LLC grew its stake in Kenvue by 13.2% in the 1st quarter. OneDigital Investment Advisors LLC now owns 21,790 shares of the company’s stock valued at $523,000 after acquiring an additional 2,538 shares during the last quarter. HM Payson & Co. purchased a new position in Kenvue during the 1st quarter valued at about $124,000. Finally, Concurrent Investment Advisors LLC increased its holdings in Kenvue by 250.0% during the 1st quarter. Concurrent Investment Advisors LLC now owns 58,135 shares of the company’s stock valued at $1,394,000 after acquiring an additional 41,527 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Trading Up 12.6%

Shares of Kenvue stock opened at $16.18 on Tuesday. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $25.17. The business’s fifty day moving average is $17.11 and its two-hundred day moving average is $20.45. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. The firm has a market cap of $31.06 billion, a PE ratio of 21.87, a P/E/G ratio of 2.07 and a beta of 0.71.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, November 6th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.During the same period last year, the company earned $0.28 earnings per share. Kenvue’s revenue was down 3.5% on a year-over-year basis. Analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 26th. Stockholders of record on Wednesday, November 12th will be issued a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a dividend yield of 5.1%. The ex-dividend date is Wednesday, November 12th. Kenvue’s dividend payout ratio is presently 112.16%.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Jefferies Financial Group reduced their price target on shares of Kenvue from $25.00 to $23.00 and set a “buy” rating on the stock in a report on Monday, October 27th. Barclays reduced their target price on Kenvue from $20.00 to $17.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 1st. Bank of America dropped their price target on Kenvue from $25.00 to $21.00 and set a “buy” rating for the company in a research report on Wednesday, October 8th. Rothschild & Co Redburn upgraded Kenvue from a “neutral” rating to a “buy” rating and reduced their price objective for the company from $22.50 to $22.00 in a research report on Friday, September 26th. Finally, Redburn Partners set a $22.00 price objective on Kenvue in a research note on Friday, September 26th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $20.17.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.